Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the change-wp-admin-login domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u168781334/domains/cashmycurrency.com/public_html/wp-includes/functions.php on line 6260
Game Changer for Diabetics? Chinese Study Shows Early Insulin Boosts Type 2 Control | The Express Tribune – Cash My Currency- Financial Updates | Business Blog Post | Financial Guest Posting Services

Game Changer for Diabetics? Chinese Study Shows Early Insulin Boosts Type 2 Control | The Express Tribune

Game Changer for Diabetics? Chinese Study Shows Early Insulin Boosts Type 2 Control | The Express Tribune

BEIJING:

Chinese scientists have demonstrated the effectiveness of early insulin therapy for newly diagnosed patients with type 2 diabetes (T2D), which can reduce the risks of stroke and hospitalization due to heart failure compared to those who have not received the treatment.

A joint research team led by Professor Weng Jianping from Anhui Medical University, and scientists from the University of Science and Technology of China, Southern Medical University, and Peking University, conducted a 24-year observational study on the treatment of 5,424 T2D patients across the country.

They found that newly diagnosed T2D patients who underwent the therapy experienced a 31 percent reduced risk of stroke and a 28 percent lower risk of hospitalization due to heart failure.

Read: ‘Healthy lifestyle helps prevent diabetes’

This study further demonstrates the effectiveness of early insulin therapy in improving biomarkers related to low-grade inflammation and endothelial function, which are known indicators of cardiovascular risk, in newly diagnosed T2D patients.

This provides compelling evidence for adopting early insulin therapy as a first-line treatment option for newly diagnosed patients.

The findings were published in the international journal of Signal Transduction and Targeted Therapy in early June.

Scroll to Top